司美格鲁肽对2型糖尿病参与者β细胞功能和血糖控制的影响:一项随机、双盲、安慰剂对照试验
这项在德国单中心开展的双盲安慰剂对照试验将75例2型糖尿病成人随机分配至每周一次皮下注射司美格鲁肽1.0 mg组或安慰剂组,治疗12周。司美格鲁肽显著改善静脉葡萄糖耐量试验第一和第二时相胰岛素分泌,降低24小时餐食试验中空腹、餐后及整体血糖和胰高血糖素反应,并耐受良好。
要点
- 司美格鲁肽1.0 mg每周一次治疗12周显著增加第一时相和第二时相胰岛素分泌。
- 24小时餐食试验显示司美格鲁肽降低空腹、餐后及整体血糖和胰高血糖素反应。
- 精氨酸刺激试验显示司美格鲁肽治疗后最大胰岛素能力增加,且耐受良好。
核心结论
- 每周一次司美格鲁肽治疗12周显著改善2型糖尿病参与者的β细胞功能和血糖控制。
研究设计与样本
- 单中心、双盲、安慰剂对照、平行组试验,在德国Profil Institut für Stoffwechselforschung开展。
- 75例年龄18-64岁、HbA1c 6.5-9.0%(47.5-74.9 mmol/mol)、BMI 20.0-35.0 kg/m2的2型糖尿病成人按1:1随机分配至每周一次皮下注射司美格鲁肽1.0 mg(0.25、0.5、1.0 mg递增)组或安慰剂组,治疗12周。
- 共同主要终点为静脉葡萄糖耐量试验测定的第一时相(AUC0-10 min)和第二时相(AUC10-120 min)胰岛素分泌从基线至治疗结束的变化。
- 另进行精氨酸刺激试验和24小时餐食刺激试验;分级葡萄糖输注试验评估接受治疗参与者和一组未治疗健康参与者的胰岛素分泌率。
主要发现
- 37例接受司美格鲁肽,38例接受安慰剂。
- 静脉葡萄糖耐量试验中,司美格鲁肽使胰岛素AUC0-10min和AUC10-120min均显著增加,估计治疗比[95%CI]分别为3.02[2.53, 3.60]和2.10[1.86, 2.37],p<0.0001。
- 24小时餐食试验显示司美格鲁肽降低空腹、餐后及整体(AUC0-24h)血糖和胰高血糖素反应(p<0.0001)。
- 精氨酸刺激试验显示司美格鲁肽治疗后最大胰岛素能力增加。
- 分级葡萄糖输注试验中,司美格鲁肽显著增加胰岛素分泌率至与健康参与者相似的水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Semaglutide is a glucagon-like peptide-1 analogue in development for the treatment of type 2 diabetes. Its effects on first- and second-phase insulin secretion and other measures of beta cell function and glycaemic control were assessed. METHODS: In this single-centre, double-blind, placebo-controlled, parallel-group trial, conducted at the Profil Institut für Stoffwechselforschung, Germany, 75 adult (aged 18-64 years) participants with type 2 diabetes (eligibility: HbA1c of 6.5-9.0% (47.5-74.9 mmol/mol); BMI 20.0-35.0 kg/m2; and treatment with diet and exercise and/or metformin monotherapy with a dose unchanged in the 30 days prior to screening) were randomised (1:1) to once-weekly s.c. semaglutide 1.0 mg (0.25, 0.5, 1.0 mg escalated) or placebo for 12 weeks. Co-primary endpoints were changes from baseline to end of treatment in the first (AUC0-10 min) and second (AUC10-120 min) insulin secretion phases, as measured by the IVGTT. An arginine stimulation test (AST) and a 24 h meal stimulation test were also conducted. A graded glucose infusion test (GGIT) assessed insulin secretion rate (ISR) in treated participants and a group of untreated healthy participants. Safety endpoints were also assessed. RESULTS: In total, 37 participants received semaglutide and 38 received placebo. Following IVGTT, for insulin, both AUC0-10min and AUC10-120min were significantly increased with semaglutide (estimated treatment ratio [95% CI] 3.02 [2.53, 3.60] and 2.10 [1.86, 2.37], respectively; p < 0.0001). The 24 h meal test showed reduced fasting, postprandial and overall (AUC0-24h) glucose and glucagon responses with semaglutide (p < 0.0001). The AST showed that maximal insulin capacity increased following semaglutide treatment. During GGIT, semaglutide significantly increased ISR to levels similar to those in healthy participants. Semaglutide was well tolerated. CONCLUSIONS/INTERPRETATION: Twelve weeks of once-weekly treatment with semaglutide significantly improved beta cell function and glycaemic control in participants with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT02212067 FUNDING: The study was funded by Novo Nordisk A/S.
引用
- Kapitza C, Dahl K, Jacobsen JB, et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017. PMID: 28526920. doi:10.1007/s00125-017-4289-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。